Vilobelimab |
Catalog No.GC72402 |
Vilobelimab (CACP - 29, ifx - 1) est un anticorps monoclonal anti - c5a dirigé contre l'allergène c5a, un produit de division du complément pro - inflammatoire qui joue un rôle central dans la médiation du dysfonctionnement des organes.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2250440-41-4
Sample solution is provided at 25 µL, 10mM.
Vilobelimab selectively neutralises C5a in a dose-dependent manner without blocking the formation of the membrane attack complex and without leading to detectable safety concerns In certain clinical studies of patients suffering from severe sepsis and septic shock[1].
References:
[1]. Michael Bauer, et al. Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study). Crit Care Explor. 2021 Nov 17;3(11):e0577.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *